

38th Vicenza Course on AKI&CRRT

a week of virtual meetings

November 2	November 3	November 4	November 5	November 6
<p>Chairs of the day: Claudio Ronco & John Kellum</p> <p>Block 1: AKI & SEPSIS</p> <p>13.30 AKI in Sepsis: mechanisms, phenotype and biotype <i>R. Bellomo</i></p> <p>13.42 Sepsis and AKI: why many trials fail? <i>J.L. Vincent</i></p> <p>13.54 Clinical evidence and sepsis: are randomized clinical trials essential? <i>C. Ince</i></p> <p>14.06 Which end points for new trials in sepsis? <i>J. Kellum</i></p> <p>14.18 Discussion</p> <p>14.23 Cappuccino with Claudio Ronco Clinical experience with SAMI - <i>C. Ronco, L. Yessayan</i></p> <p>Block 2: AKI & BIOMARKERS</p> <p>14.30 Do we need a new definition of AKI? <i>N. Pannu</i></p> <p>14.42 Using biomarkers to improve AKI definition <i>M. Ostermann</i></p> <p>14.54 Using biomarkers to manage AKI <i>A. Zarbock</i></p> <p>15.06 PSP in the early diagnosis of sepsis <i>P. Eggimann</i></p> <p>15.18 Discussion</p> <p>15.23 Meet the expert Experts discuss the challenge of AKI in the cath lab Chairman: <i>C. Ronco</i> Speakers: <i>P. McCullough, A. La Manna</i></p> <p>Block 3: AKI CONTINUUM</p> <p>15.38 The continuum of AKI <i>R. Mehta</i></p> <p>15.50 From AKI to AKD and CKD <i>A. Kattah</i></p> <p>16.02 Patterns of AKI Recovery <i>L. Forni</i></p> <p>16.14 Discussion</p> <p>16.19 Sponsored symposium Enhancing extracorporeal blood purification in the critically ill Chairman: <i>C. Ronco</i> From sepsis to COVID-19: Where are we on the learning curve? <i>P. Pickkers</i> A Registry experience - <i>S. Romagnoli</i></p> <p>17.04 Adjourn</p>	<p>12.15 Sponsored symposium TBA</p> <p>Chairs of the day: Claudio Ronco & Marlies Ostermann</p> <p>Block 4: CRRT START</p> <p>13.30 CRRT initiation: I want an early start <i>L. Forni</i></p> <p>13.40 CRRT initiation: I want to wait and see <i>M. Meersch</i></p> <p>13.50 What does the STARRT Trial suggest? <i>S. Bagshaw</i></p> <p>14.10 Discussion</p> <p>14.15 Meet the expert Is endotoxemia relevant in COVID-19? Chairman: <i>K. Kashani</i> Endotoxemia as a risk factor for AKI in COVID-19 - <i>S. Mallipattu</i> Endotoxemia in COVID-19: prevalence and relevance - <i>TBD</i></p> <p>Block 5: CRRT QUALITY</p> <p>14.30 Quality measures AKI management <i>R. Mehta</i></p> <p>14.45 Measuring Quality of a CRRT Programme <i>T. Mottes</i></p> <p>15.00 Key Points in measuring Quality <i>K. Kashani</i></p> <p>15.10 Discussion</p> <p>15.15 Sponsored symposium Lessons learned and extended therapies in CRRT Chairman: <i>C. Ronco</i> Citrate anticoagulation in convective and diffusive CRRT <i>A.G. Schneider</i> ARF: Acute Renal and Respiratory failure. The need for the combination of therapies - <i>V.M. Ranieri</i></p> <p>Block 6: ULTRAFILTRATION</p> <p>15.45 Net UF and mortality in CRRT <i>R. Murugan</i></p> <p>15.57 Net UF and the hemodynamics <i>S. Romagnoli</i></p> <p>16.09 Net UF and Renal Recovery <i>R. Murugan</i></p> <p>16.22 Discussion</p> <p>16.27 Sponsored symposium The Use of Biomarkers in the Management of Acute Kidney Injury Chairman: <i>C. Ronco</i> AKI in the critically ill - <i>L. Forni</i> Post cardiothoracic surgery AKI - <i>D. Engelman</i></p> <p>17.12 Adjourn</p>	<p>Chairs of the day: Claudio Ronco & John Prowle</p> <p>Block 7: ORGAN CROSSTALK</p> <p>13.30 Heart - Kidney Interaction <i>P. McCullough</i></p> <p>13.42 Lung and Kidney interaction <i>F. Husain-Syed</i></p> <p>13.54 Cardiorenal interactions and NGAL <i>Y. Shacham</i></p> <p>14.06 Discussion</p> <p>14.11 Meet the expert NGAL as an AKI biomarker in COVID-19 related AKI Chairman: <i>C. Ronco</i> Speakers: <i>C. Albert, K. Doi</i></p> <p>Block 8: PERIOPERATIVE KIDNEY CARE</p> <p>14.30 Perioperative AKI: The Cambridge resolutions <i>A. Shaw</i></p> <p>14.42 Perioperative AKI: Prevention Strategies <i>S. Bell</i></p> <p>14.54 Outcomes after Perioperative AKI <i>M. Ostermann</i></p> <p>15.06 Discussion</p> <p>15.11 Meet the expert Evolution of Vitamin-E interactive membrane for the Super-HD dialysis technique - <i>C. Ronco</i></p> <p>Block 9: AKI and ICT</p> <p>15.30 Augmented Human Intelligence and AKI management <i>K. Kashani</i></p> <p>15.45 AKI: from Big Data to bedside <i>S. Bagshaw</i></p> <p>16.00 What's next? <i>M. Rosner</i></p> <p>16.10 Discussion</p> <p>16.15 Sponsored symposium Septic Shock and COVID-19: the dysregulated host response Chairman: <i>C. Ronco</i> Endotoxic Shock and COVID-19: role of Polymyxin B Hemoperfusion - <i>S. De Rosa</i> Septic AKI: dialysis membrane as therapeutic approach <i>V. Cantaluppi</i></p> <p>17.00 Adjourn</p>	<p>Chairs of the day: Claudio Ronco & Zaccaria Ricci</p> <p>Block 10: CRRT MEMBRANES</p> <p>13.30 The promise of HCO and MCO membranes <i>T. Reis</i></p> <p>13.42 New membranes for CRRT <i>G. Castellano</i></p> <p>13.54 Surface modified membranes <i>G. Villa</i></p> <p>14.06 Discussion</p> <p>14.11 Cappuccino with Claudio Ronco Update on fluids and electrolytes: are there still unmet needs? <i>C. Ronco</i></p> <p>Block 11: SORBENTS</p> <p>14.30 Endotoxin removal in sepsis <i>V. Cantaluppi</i></p> <p>14.42 Cytokine removal in immunodysregulation <i>T. Rimmelé</i></p> <p>14.54 Sequential extracorporeal therapy <i>S. De Rosa</i></p> <p>15.06 Discussion</p> <p>15.00 Meet the expert Endotoxemia and PMX therapy: a picture from the real clinical practice Chairman: <i>C. Ronco</i> Speaker: <i>S.L. Cutuli</i></p> <p>Block 12: ECOS</p> <p>15.30 Extracorporeal Lung Support <i>P. Navalesi</i></p> <p>15.40 Extracorporeal Cardiac support <i>A. Kazory</i></p> <p>15.50 Extracorporeal Liver Support <i>M. Nadim</i></p> <p>16.00 Extracorporeal support in infants <i>S. Goldstein</i></p> <p>16.10 Discussion</p> <p>16.15 Sponsored symposium Clinical path for CRRT NICU adoption: modality, technology and barriers Chairman: <i>C. Ronco</i> Speakers: <i>E. Vidal, S. Goldstein</i></p> <p>17.00 Adjourn</p>	<p>Chairs of the day: Claudio Ronco & Mitchell Rosner</p> <p>Block 13: FLUID MANAGEMENT</p> <p>13.30 Diuretics or Extracorporeal UF <i>M. Ostermann</i></p> <p>13.42 The danger of fluid overload <i>K. D. Liu</i></p> <p>13.54 How to assess fluid status during CRRT <i>E. See</i></p> <p>14.06 Discussion</p> <p>14.11 Sponsored educational activity TBA</p> <p>Block 14: SPECIAL TOPICS</p> <p>14.30 Contrast-induced AKI in special patient categories <i>M. Rosner</i></p> <p>14.42 New insights in atypical hemolytic uremic syndrome <i>G. Ardissino</i></p> <p>14.54 Moving from acute RRT to chronic RRT <i>A. Tolwani</i></p> <p>15.06 Discussion</p> <p>15.11 Meet the expert New challenges in Acute Lung Injury during the era of Covid-19: from ECOO2R to complete oxygenation Chairman: <i>C. Ronco</i> Speaker: <i>A. Pesenti</i></p> <p>Block 15: AKI and COVID-19</p> <p>15.30 Epidemiology <i>R. Mehta</i></p> <p>15.40 Mechanisms <i>J. Kellum</i></p> <p>15.50 Prevention of AKI <i>L. Forni</i></p> <p>16.00 CRRT and renal support <i>J. Prowle</i></p> <p>16.10 Extracorporeal Blood Purification Techniques <i>C. Ronco</i></p> <p>16.20 Discussion</p> <p>16.30 Sponsored symposium Anticoagulation in CRRT: State-of-the-art in 2020 Chairman: <i>C. Ronco</i> Citrate vs. heparin anticoagulation in CRRT - What to recommend - <i>D. Khadzhynov</i> Procoagulant state with COVID-19 - Need to adapt anticoagulation in CRRT? - <i>A.G. Schneider</i></p> <p>17.15 Adjourn</p>